1. Scrip
  2. >>Focus On Asia
  3. >>China

China Biotech IPOs Remain In Deep Freeze, Hong Kong Fares Better

 
• By Dexter Jie Yan

Amid stricter regulatory reviews of applications for IPOs across all sectors, such offerings in biotech have been in hiatus on the Chinese mainland in 2024 to date. Meanwhile, three bioventures raised a combined $217.8m as they floated on the Hong Kong Stock Exchange in the first half.

IPO
China freeze on biopharma IPOs continues, although Hong Kong sees several floats • Source: Shutterstock

Initial public offerings (IPOs) for innovative, drug-focused biotechs have remained elusive in the Chinese mainland well into the second half of 2024, since the country’s top securities regulator put a lid on go-public procedures by applicants across all industry sectors in March.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific

 
• By Anju Ghangurde

Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.

More from Focus On Asia

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

What Is Fuelling Cell And Gene Therapies In India?

 
• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By Jung Won Shin

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.